Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...

Nelson Peltz’s Trian Fund Management plans to push Solventum (SOLV) to separate more of its businesses after the company sold its filtration ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

The most notable increase was Solventum Corp (NYSE:SOLV), with an additional 1,336,564 shares, bringing the total to 8,462,819 shares. This adjustment represents a significant 18.76% increase in share ...

Nelson Peltz’s Trian Partners sent a letter to the shareholders of Solventum (SOLV), saying the company trades at a discount to peers and 3M (MMM), Scott Wapner of CNBC reports. Trian believes ...

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company's $4.1 billion deal to sell its filtration ...

Nelson Peltz’s Trian Fund Management disclosed in an SEC filing its holdings as of December 31, 2024. Trian increased its stake in a number of ...

Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Solventum Shares Are Up Today ... its bioproduction portfolio with expected long-term growth. Vandana Singh Nelson Peltz's Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election ...